Immunotherapy of acute myeloid leukemia

A. E. Frankel, M. R. Baer, D. E. Hogge, R. K. Stuart

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as well. Nevertheless, a number of these patients may be salvaged and achieve remissions with allogeneic stem cell transplants. In such cases, the pre-transplant conditioning regimens do not appear to account for the entire anti-leukemic efficacy. Immunological mechanisms for blast killing appear critical. There is tissue culture, animal and clinical evidence that stimulated donor T cells can recognize and kill leukemic blasts through recognition of alloantigens, differentiation antigens or leukemia-specific antigens as targets. We will review the molecular mechanisms for the generation of anti-leukemic T cells and discuss methods to improve the specificity and intensity of anti-leukemic T cell responses in the setting of allogeneic stem cell transplants, donor lymphocyte infusions, autologous anti-leukemic T cell infusions, and vaccine use in AML patients.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalCurrent Pharmaceutical Biotechnology
Volume2
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Acute Myeloid Leukemia
Immunotherapy
T-Lymphocytes
Transplants
Stem Cells
Tissue Donors
Recurrence
Isoantigens
Differentiation Antigens
Cytotoxins
Combination Drug Therapy
Leukemia
Vaccines
Lymphocytes
Antigens
Drug Therapy
Pharmaceutical Preparations
Thomsen-Friedenreich antibodies

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Biotechnology

Cite this

Immunotherapy of acute myeloid leukemia. / Frankel, A. E.; Baer, M. R.; Hogge, D. E.; Stuart, R. K.

In: Current Pharmaceutical Biotechnology, Vol. 2, No. 3, 2001, p. 209-215.

Research output: Contribution to journalArticle

Frankel, A. E. ; Baer, M. R. ; Hogge, D. E. ; Stuart, R. K. / Immunotherapy of acute myeloid leukemia. In: Current Pharmaceutical Biotechnology. 2001 ; Vol. 2, No. 3. pp. 209-215.
@article{d085b7d114b0408f9849d10364c54988,
title = "Immunotherapy of acute myeloid leukemia",
abstract = "Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as well. Nevertheless, a number of these patients may be salvaged and achieve remissions with allogeneic stem cell transplants. In such cases, the pre-transplant conditioning regimens do not appear to account for the entire anti-leukemic efficacy. Immunological mechanisms for blast killing appear critical. There is tissue culture, animal and clinical evidence that stimulated donor T cells can recognize and kill leukemic blasts through recognition of alloantigens, differentiation antigens or leukemia-specific antigens as targets. We will review the molecular mechanisms for the generation of anti-leukemic T cells and discuss methods to improve the specificity and intensity of anti-leukemic T cell responses in the setting of allogeneic stem cell transplants, donor lymphocyte infusions, autologous anti-leukemic T cell infusions, and vaccine use in AML patients.",
author = "Frankel, {A. E.} and Baer, {M. R.} and Hogge, {D. E.} and Stuart, {R. K.}",
year = "2001",
doi = "10.2174/1389201013378699",
language = "English (US)",
volume = "2",
pages = "209--215",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Immunotherapy of acute myeloid leukemia

AU - Frankel, A. E.

AU - Baer, M. R.

AU - Hogge, D. E.

AU - Stuart, R. K.

PY - 2001

Y1 - 2001

N2 - Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as well. Nevertheless, a number of these patients may be salvaged and achieve remissions with allogeneic stem cell transplants. In such cases, the pre-transplant conditioning regimens do not appear to account for the entire anti-leukemic efficacy. Immunological mechanisms for blast killing appear critical. There is tissue culture, animal and clinical evidence that stimulated donor T cells can recognize and kill leukemic blasts through recognition of alloantigens, differentiation antigens or leukemia-specific antigens as targets. We will review the molecular mechanisms for the generation of anti-leukemic T cells and discuss methods to improve the specificity and intensity of anti-leukemic T cell responses in the setting of allogeneic stem cell transplants, donor lymphocyte infusions, autologous anti-leukemic T cell infusions, and vaccine use in AML patients.

AB - Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as well. Nevertheless, a number of these patients may be salvaged and achieve remissions with allogeneic stem cell transplants. In such cases, the pre-transplant conditioning regimens do not appear to account for the entire anti-leukemic efficacy. Immunological mechanisms for blast killing appear critical. There is tissue culture, animal and clinical evidence that stimulated donor T cells can recognize and kill leukemic blasts through recognition of alloantigens, differentiation antigens or leukemia-specific antigens as targets. We will review the molecular mechanisms for the generation of anti-leukemic T cells and discuss methods to improve the specificity and intensity of anti-leukemic T cell responses in the setting of allogeneic stem cell transplants, donor lymphocyte infusions, autologous anti-leukemic T cell infusions, and vaccine use in AML patients.

UR - http://www.scopus.com/inward/record.url?scp=0034856943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034856943&partnerID=8YFLogxK

U2 - 10.2174/1389201013378699

DO - 10.2174/1389201013378699

M3 - Article

VL - 2

SP - 209

EP - 215

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 3

ER -